CYTK
HealthcareCytokinetics, Incorporated · Biotechnology · $10B
What is Cytokinetics, Incorporated?
Cytokinetics is a late-stage biopharmaceutical company focused on developing small molecule drug candidates that target muscle function and contractility to treat serious diseases.
Cytokinetics engineers drug candidates designed to activate or inhibit muscle proteins involved in heart and skeletal muscle diseases. The company generates no product revenue yet, funding operations through partnerships — including a strategic alliance with Astellas Pharma — and capital markets while advancing multiple candidates through late-stage clinical trials.
Incorporated in 1997 and headquartered in South San Francisco, California.
- Aficamten — cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy
- Omecamtiv mecarbil — cardiac myosin activator in Phase III for heart failure
- Reldesemtiv — skeletal muscle troponin activator in Phase III for ALS and spinal muscular atrophy
- CK-136 and CK-3772271 — early-stage cardiac candidates in Phase I trials
Is CYTK a Good Stock to Buy?
UQS Score rates CYTK as Below Average overall, reflecting the realities of a pre-revenue clinical-stage biotech.
The Growth pillar stands out as the clearest positive, driven by a rich late-stage pipeline. The Risk pillar also rates favorably, suggesting the company maintains a manageable financial risk profile relative to peers at this stage.
Quality and Moat both rate Weak, consistent with a company that has not yet commercialized a product. Valuation is Elevated, meaning the market has priced in significant pipeline success.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CYTK pay dividends?
No — Cytokinetics, Incorporated does not currently pay a dividend.
Cytokinetics does not pay a dividend. As a clinical-stage biopharmaceutical company, available capital is directed toward advancing its drug pipeline through costly late-stage trials rather than returning cash to shareholders. Income-focused investors should factor this into their assessment.
When does CYTK report earnings?
Cytokinetics reports earnings on a quarterly cadence, typical for US-listed equities.
As a pre-revenue company, quarterly results center on pipeline progress, cash runway, and operating expenses rather than traditional revenue or profit metrics. Clinical trial readouts tend to move the stock more than earnings beats or misses.
For the most recent quarter's results, visit Cytokinetics' investor relations page directly.
CYTK Price History
+201.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Cytokinetics, Incorporated?
Based on Cytokinetics, Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Cytokinetics do?
Cytokinetics discovers and develops small molecule drugs that target muscle proteins involved in heart and skeletal muscle diseases. Its pipeline includes late-stage candidates for hypertrophic cardiomyopathy, heart failure, ALS, and spinal muscular atrophy. The company has not yet commercialized a product.
Does CYTK pay dividends?
No. Cytokinetics does not pay a dividend. The company reinvests all available capital into its clinical pipeline. Investors seeking income should look elsewhere; CYTK is primarily a pipeline-driven growth story.
When does CYTK report earnings?
Cytokinetics follows a standard quarterly reporting schedule. Because it is pre-revenue, pipeline updates and cash position typically matter more than traditional earnings figures. Check the company's investor relations page for the current reporting calendar.
Is CYTK a good stock to buy?
UQS Score rates CYTK as Below Average, reflecting weak Quality and Moat scores alongside an Elevated Valuation. The Growth pillar is a relative bright spot. Whether it suits your portfolio depends on your risk tolerance for clinical-stage biotech. View the full breakdown with a Pro account.
Is CYTK overvalued?
The UQS Valuation pillar for CYTK is rated Elevated, suggesting the market has priced in meaningful pipeline success. This is common for late-stage biotechs with high-value candidates, but it also means limited margin of safety if trials disappoint.
What is CYTK's market cap bracket?
Cytokinetics is classified as a mid-cap company. This places it among the larger clinical-stage biotechs, reflecting investor expectations around its late-stage pipeline rather than current revenues.
Is CYTK a long-term quality indicator?
As a long-term quality indicator, CYTK scores Below Average on the UQS composite. Weak Quality and Moat pillars reflect its pre-commercial status. Long-term quality potential depends heavily on whether pipeline candidates reach commercialization successfully.
What is the main competitive advantage of Cytokinetics?
Cytokinetics' differentiation lies in its specialized focus on muscle biology and its proprietary small molecule platform targeting cardiac and skeletal muscle proteins. Its strategic alliance with Astellas Pharma also provides development resources and validation for its approach.
Unlock Full CYTK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and pipeline risk context
- ✓Compare CYTK against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available to Pro members
Pro Analysis
CYTK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 34.3 | 18.8 | 17.0 | 65.0 | 82.4 | 0.0 | -0.3 |
| May 10, 2026 | 34.6 | 20.0 | 17.0 | 65.0 | 82.4 | 0.0 | +0.3 |
| Apr 2, 2026 | 34.3 | 18.8 | 17.0 | 65.0 | 82.4 | 0.0 | — |
CYTK — Pillar Breakdown
Quality
— 18.8/100 (25%)Cytokinetics, Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 65.0/100 (20%)Cytokinetics, Incorporated demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Cytokinetics, Incorporated carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Cytokinetics, Incorporated appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Cytokinetics, Incorporated operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CYTK.
Score Composition
Financial Data
More Stock Analysis
How is the CYTK UQS Score Calculated?
The UQS (Unified Quality Score) for Cytokinetics, Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cytokinetics, Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cytokinetics, Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.